Mendelian Randomization Analyses for Selection of Therapeutic Targets for Cardiovascular Disease Prevention: a Note of Circumspection

Cardiovasc Drugs Ther. 2016 Feb;30(1):65-74. doi: 10.1007/s10557-016-6642-9.

Abstract

Genetic factors identified from genome-wide association studies have been used to understand causative variants for complex diseases. Studies conducted on large populations of individuals from many geographical regions have provided insights into genetic pathways involved in the causal pathway for atherosclerotic cardiovascular disease. A single genetic trait may ineffectively evaluate the pathway of interest, and it may not account for other complementary genetic pathways that may be activated at various stages of the disease process or evidence-based therapies that alter the molecular and cellular milieu.

Keywords: Atherosclerosis; Cholesterol ester transfer protein; Diabetes; Ezetimibe; Genetics; Inflammation; Interleukin 6; Lipoproteins; Mendelian randomization; PCSK9; Secretory phospholipase A2; Statins.

Publication types

  • Review

MeSH terms

  • Atherosclerosis / drug therapy
  • Cardiovascular Agents / therapeutic use*
  • Cardiovascular Diseases / drug therapy*
  • Genome-Wide Association Study / methods
  • Humans
  • Mendelian Randomization Analysis / methods*
  • Risk Factors

Substances

  • Cardiovascular Agents